CA2795853A1 - Methods and compositions for inhibiting hiv transmission - Google Patents

Methods and compositions for inhibiting hiv transmission Download PDF

Info

Publication number
CA2795853A1
CA2795853A1 CA2795853A CA2795853A CA2795853A1 CA 2795853 A1 CA2795853 A1 CA 2795853A1 CA 2795853 A CA2795853 A CA 2795853A CA 2795853 A CA2795853 A CA 2795853A CA 2795853 A1 CA2795853 A1 CA 2795853A1
Authority
CA
Canada
Prior art keywords
hiv
env
fragment
animal
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2795853A
Other languages
English (en)
French (fr)
Inventor
Grant Thomas Rawlin
Damian Francis John Purcell
Robert John Center
Marit Kramski
Roy Michael Robins-Browne
Gottfried Lichti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Luath Technology Pty Ltd
Reef Pharmaceuticals Pty Ltd
University of Melbourne
Immuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luath Technology Pty Ltd, Reef Pharmaceuticals Pty Ltd, University of Melbourne, Immuron Ltd filed Critical Luath Technology Pty Ltd
Publication of CA2795853A1 publication Critical patent/CA2795853A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2795853A 2010-04-09 2011-04-11 Methods and compositions for inhibiting hiv transmission Abandoned CA2795853A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32239910P 2010-04-09 2010-04-09
US61/322,399 2010-04-09
PCT/AU2011/000407 WO2011123900A1 (en) 2010-04-09 2011-04-11 Methods and compositions for inhibiting hiv transmission

Publications (1)

Publication Number Publication Date
CA2795853A1 true CA2795853A1 (en) 2011-10-13

Family

ID=44761932

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2795853A Abandoned CA2795853A1 (en) 2010-04-09 2011-04-11 Methods and compositions for inhibiting hiv transmission

Country Status (12)

Country Link
US (1) US20130022619A1 (https=)
EP (1) EP2555798B1 (https=)
JP (1) JP6026402B2 (https=)
CN (1) CN103167881B (https=)
AP (1) AP3469A (https=)
AU (2) AU2011238431B2 (https=)
BR (1) BR112012025678A2 (https=)
CA (1) CA2795853A1 (https=)
MX (1) MX343505B (https=)
RU (1) RU2594249C2 (https=)
WO (1) WO2011123900A1 (https=)
ZA (1) ZA201207790B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049524A4 (en) * 2013-09-27 2017-06-14 Duke University Hiv-1 mother-to-child transmission correlates of protection and vaccine
CN103736100B (zh) * 2013-12-25 2017-06-09 南方医科大学 预防hiv性传播的杀微生物剂酸酐修饰抗sevi多克隆抗体
JP6955487B2 (ja) * 2015-09-24 2021-10-27 アブビトロ， エルエルシー Ｈｉｖ抗体組成物および使用方法
WO2017062071A1 (en) * 2015-10-07 2017-04-13 Eca Medical Instruments Gearless washer spring torque drive
US10973679B2 (en) * 2016-02-12 2021-04-13 Adam Arreola STD detecting condom
JP2023528992A (ja) 2020-06-10 2023-07-06 ザ ユニバーシティー オブ メルボルン Ｈｉｖ－１抗体
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
JP2024521987A (ja) 2021-05-12 2024-06-05 アプライド バイオメディカル サイエンス インスティチュート ジスルフィド結合した結合ポリペプチドのスクリーニング及び発現の方法
JP7421610B1 (ja) 2022-08-18 2024-01-24 株式会社マーベラス ゲーム装置
AU2023379740A1 (en) 2022-11-16 2025-05-29 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2026073047A1 (en) 2024-09-27 2026-04-02 Applied Biomedical Science Institute Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
DK1190101T3 (da) * 1999-06-24 2009-08-03 Univ Johns Hopkins Sammensætninger og fremgangsmåder til at forebygge transepithelial overförsel af HIV
MXPA03002643A (es) * 2000-09-28 2003-06-19 Chiron Corp Composiciones de microparticulas y metodos para producirlas.
US7939083B2 (en) * 2006-10-23 2011-05-10 Progenics Pharmaceuticals Inc. Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
WO2009058989A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines
WO2010096042A1 (en) * 2008-10-30 2010-08-26 Dana-Farber Cancer Institute Mimotopes of hiv env

Also Published As

Publication number Publication date
JP2013523783A (ja) 2013-06-17
AP2012006519A0 (en) 2012-10-31
RU2012142999A (ru) 2014-05-20
MX343505B (es) 2016-11-04
JP6026402B2 (ja) 2016-11-16
ZA201207790B (en) 2013-06-26
BR112012025678A2 (pt) 2017-07-18
AP3469A (en) 2015-11-30
CN103167881A (zh) 2013-06-19
MX2012011574A (es) 2013-03-05
RU2594249C2 (ru) 2016-08-10
EP2555798B1 (en) 2016-06-22
EP2555798A4 (en) 2013-11-20
US20130022619A1 (en) 2013-01-24
EP2555798A1 (en) 2013-02-13
AU2017265055A1 (en) 2019-06-06
AU2011238431A1 (en) 2012-11-08
CN103167881B (zh) 2017-06-16
WO2011123900A1 (en) 2011-10-13
AU2011238431B2 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
AU2011238431B2 (en) Methods and compositions for inhibiting HIV transmission
Morein et al. Current status and potential application of ISCOMs in veterinary medicine
TWI320715B (en) Improved mycoplasma hyopneumoniae bacterin vaccine
RU2407749C2 (ru) Иммуногенная композиция и способ разработки вакцины, основанной на слитом белке
US7262270B2 (en) Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo
WO1999012416A1 (en) T-independent conjugate-vaccines
Machado et al. Adaptive immunity in the postpartum uterus: Potential use of vaccines to control metritis
Hamajima et al. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response
AU2021203071B2 (en) Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition
Pavot et al. Recent progress in HIV vaccines inducing mucosal immune responses
JPH09504296A (ja) Ｈｉｖ粘膜感染の阻止
CA2813612A1 (en) Methods and compositions using anti-lps ligands for the treatment and prevention of inflammatory disorders
US20200140529A1 (en) Methods and compositions for inhibiting hiv transmission
AU2021204628B2 (en) Methods and compositions related to accelerated humoral affinity
US20240277829A1 (en) Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
WO2002032452A1 (en) Composition for aids and method producing it
Zinckgraf et al. Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide
Limbert Development of an Effective Chlamydial Vaccine Using Combination Adjuvants
WO2025250861A1 (en) Broadly neutralizing anti-hcmv antibodies and uses thereof
Morris MA (Cantab.), MBBS (Lond.), MRCP (UK)
Vyse et al. P1070 Susceptibility to rubella in females born 1996–2003: a potential congenital rubella syndrome iceberg?
Roodbari et al. P1068 From insects to man: identification of virulence factors involved in the adaptation of the emerging pathogen Photorhabdus asymbiotica to human hosts
Roodbari et al. P1069 Clustered epitopes within the Gag-env HIV-1 fusion proteins DNA vaccine enhance immune responses in mice

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160324

FZDE Discontinued

Effective date: 20210831